Palosuran hydrochloride
CAS No. ——
Palosuran hydrochloride ( —— )
Catalog No. M17710 CAS No. ——
Palosuran is a new potent and specific antagonist of the human UT receptor with an IC50 of 3.6±0.2 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 188 | Get Quote |
|
| 10MG | 292 | Get Quote |
|
| 25MG | 474 | Get Quote |
|
| 50MG | 677 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePalosuran hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionPalosuran is a new potent and specific antagonist of the human UT receptor with an IC50 of 3.6±0.2 nM.
-
DescriptionPalosuran is a new potent and specific antagonist of the human UT receptor with an IC50 of 3.6±0.2 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorUrotensin Receptor (GPR14)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight454.99
-
Molecular FormulaC25H31ClN4O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCl.Cc2nc1ccccc1c(c2)NC(=O)NCCN3CCC(O)(CC3)Cc4ccccc4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Clozel M, et al. J Pharmacol Exp Ther, 2004, 311(1):204-212.
molnova catalog
related products
-
mTOR inhibitor 9d
mTOR inhibitor 9d is a dual inhibitor of the protein kinases mTOR and PI3K with an mTOR IC50 value of 0.31 nm, and can be used for the treatment of leukemia, skin cancer, breast cancer, lung cancer and colon cancer.
-
PI3Kδ-IN-3
PI3Kδ-IN-3 (TC KHNS 11) is a PI3Kδ inhibitor with an IC50 value of 9 nM.PI3Kδ-IN-3 has a favorable pharmacokinetic profile and inhibits B cell function.
-
iMDK
iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.
Cart
sales@molnova.com